Laguna Bio disclosed a therapeutics program using a highly attenuated Listeria monocytogenes strain engineered to stimulate multifactorial immune responses and expand gamma delta T cells; the company plans early‑stage testing in pediatric leukemia. Founders Jonathan Kotula, Dan Portnoy and Russell Carrington framed the approach as a ‘systems‑level’ immune activation strategy that combines microbial immunostimulation with principles from cell and antibody therapies. Laguna is positioning a live‑attenuated microbial platform that can be dosed repeatedly to elicit durable innate and adaptive responses. Listeria‑based approaches carry regulatory and manufacturing implications because live biologics require specialized safety testing, containment, and clinical monitoring; Laguna says its strain is highly attenuated to mitigate safety risks. The disclosure is notable for investors and immunotherapy developers given renewed interest in engineered microbes as cancer therapeutics.